However, data are limited regarding the potential benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in this subgroup.<h4>Methods</h4>We conducted a population-based cohort study between May 1, 2016, and December 31, 2021 using Taiwan's National Health Insurance (NHI) Research Database to examine the association between SGLT2is use and outcome in patients with T2D and nonalbuminuric CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.